Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tenofovir
Drug ID BADD_D02154
Description Tenofovir is an acyclic nucleotide diester analog of adenosine monophosphate.[A37693] In the most strict sense and due to the fact that it presents a phosphate group bound to the nitrogenous base, it is determined as an actual nucleotide analog.[A37693] The antiviral activities of tenofovir were first reported in 1993 and this agent was commercially available since 2008 in the form of [tenofovir disoproxil] and [tenofovir alafenamide] in order to obtain oral bioavailability.[A18473, A178360]
Indications and Usage Tenofovir has been shown to be effective against HIV, herpes simplex virus-2, and hepatitis B virus.[A178330] To know more about the specific product indications, please visit the information in the orally available forms of tenofovir, [tenofovir alafenamide] and [tenofovir disoproxil].
Marketing Status experimental; investigational
ATC Code J05AF07
DrugBank ID DB14126
KEGG ID D06074
MeSH ID D000068698
PubChem ID 464205
TTD Drug ID D0D9HW
NDC Product Code Not Available
UNII 99YXE507IL
Synonyms Tenofovir | 9-(2-Phosphonylmethoxypropyl)adenine | 9-PMPA (tenofovir) | 9-(2-Phosphonomethoxypropyl)adenine | 9-(2-Phosphonylmethoxypropyl)adenine, (S)-isomer | 9-(2-Phosphonylmethoxypropyl)adenine, (+-)-isomer | Tenofovir Disoproxil Fumarate | Disoproxil Fumarate, Tenofovir | Fumarate, Tenofovir Disoproxil | Tenofovir Disoproxil | Disoproxil, Tenofovir | 9-(2-Phosphonylmethoxypropyl)adenine, (R)-isomer - T357098 | (R)-9-(2-phosphonylmethoxypropyl)adenine | Viread
Chemical Information
Molecular Formula C9H14N5O4P
CAS Registry Number 147127-20-6
SMILES CC(CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Erectile dysfunction21.03.01.007; 19.08.04.0010.016479%
Renal injury20.01.03.015; 12.01.05.0010.189414%Not Available
Diabetic nephropathy20.05.03.011; 14.07.02.003; 05.07.02.0030.001939%Not Available
Hepatobiliary disease09.01.08.003--Not Available
Hyperlipidaemia14.08.03.0010.001939%
Renal impairment20.01.03.0100.084529%Not Available
Unevaluable event08.01.03.0510.029856%Not Available
Hypophagia19.09.01.004; 14.03.01.006; 07.01.06.0100.004847%Not Available
Chronic kidney disease20.01.03.0170.352849%
Immune reconstitution inflammatory syndrome10.02.01.043; 08.06.02.0140.003877%Not Available
Bone loss15.02.04.0200.147538%Not Available
Treatment failure08.06.01.017--Not Available
Liver injury09.01.07.022; 12.01.17.0120.016867%Not Available
Low birth weight baby18.04.02.0030.006786%Not Available
Focal segmental glomerulosclerosis20.05.01.0030.003877%Not Available
Renal cell carcinoma20.01.04.003; 16.08.02.0020.002908%Not Available
Fasting26.01.02.001--Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.004--
Acute kidney injury20.01.03.0160.079488%
Foetal growth restriction18.03.01.0020.004847%
Drug-induced liver injury12.03.01.044; 09.01.07.0230.010663%Not Available
Hepatic cancer09.04.02.008; 16.07.02.0040.029081%Not Available
Hepatocellular carcinoma16.07.02.005; 09.04.02.0100.035867%Not Available
Abortion threatened18.01.04.0030.001939%Not Available
Cryoglobulinaemia24.12.04.007; 10.04.04.0130.001939%Not Available
IgA nephropathy10.02.01.063; 20.05.01.0160.003877%Not Available
Neonatal respiratory distress syndrome22.11.02.010; 18.04.10.0030.001939%Not Available
Small for dates baby18.04.02.0020.001939%Not Available
Terminal state08.01.03.0790.001939%Not Available
Cholestasis of pregnancy18.02.04.003; 09.01.01.0130.002908%Not Available
The 9th Page    First    Pre   9 10    Next   Last    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene